Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Attractive market fundamentals | Leadership and scale | Multiple growth drivers | Margin improvement | Attractive financial outlook | Compelling sustainability story
Global leadership and scale; #1 in Europe, Sandoz biggest market
Breakdown of global Generics and Biosimilars players by region1
Gross sales, in USD bn
SANDOZ
Company A
Company B
Company C
Company D
3.4
Company E
3.0
Europe
North America
International
6.7
9.1
11.2
11.9
#1 in stable and profitable
European market
At scale but not over-exposed
to North America
Targeted presence
in International
1. Based on Company analysis using data from IQVIA MIDAS MAT 12-2022 data in LCUSD at gross price, excluding ATC J7,K,T and V, NFC V and Z and certain sizeable markets with no or limited Sandoz operations; Biocomparable, Early Entry Generics
and Generics as defined by IQVIA.
11
Management Presentation
SANDOZView entire presentation